Using The
world's data
to fight disease
Using The
world's data
to fight disease
New Insights
New Opportunity
New Insights
New Opportunity

GENETICS | EPIGENETICS | SYSTEMS BIOLOGY | BIG DATA

GENETICS | EPIGENETICS | SYSTEMS BIOLOGY | BIG DATA

THE WORLD'S
FIRST SUPPLEMENT
PROTOCOLS
THE WORLD'S FIRST
SUPPLEMENT PROTOCOLS

DESIGNED TO TARGET
CRITICAL GENES IN
DISEASE

DESIGNED TO TARGET CRITICAL
GENES IN DISEASE

Targeted
Healthcare.
Targeted
Healthcare.
Powered by science.
Powered by science.
previous arrowprevious arrow
next arrownext arrow
Slider

Epigenetics &
The Fight Against Disease

Every cell in our body has the same genetic code. However, to fulfill important and unique roles within our body, genes are expressed differently. This is called epigenetics; what differentiates the function of each cell.

If this process becomes dysregulated, disease can form and progress. Understanding exactly what genes have abnormal expression is the foundation of disease and informs everything we do at EDS.

Our mission is to improve quality of life and reverse disease by leveraging the world’s research.

cancer division

Our first division is expanding quickly with the release of OncoSC Breast Support Protocol - the first of it's kind to target genes associated with cancer.

Active research

Our team is working hard transitioning to other types of diseases and will be launching Neuro-Aging and Autoimmune divisions in the upcoming year.

For providers

We leverage a multidisciplinary approach to gene expression to create optimized self-care protocols. Discover how our plans can assist your patients.

Image is not available
OncoSC Breast
Support Product Launch

EDS to finalize breast support
protocol following exciting pre-trial results. The plans will be available in 2018.

EDS  and University of Maryland Baltimore County (UMBC) have agreed to provide access to UMBC’s laboratories and graduate students in support of EDS’s science and tech-driven breast cancer formulations and research initiatives.

Image is not available
EDS x UMBC
AAIC
EDS at AAIC

EDS will be presenting research
at the Alzheimer's Association
International Conference in
Chicago July 2018.

Image is not available

EDS will be speaking at the
Alzheimer's Disease International's
33rd Conference in Chicago July 2018.

EDS at ADI
previous arrowprevious arrow
next arrownext arrow
Slider

What the experts are saying

See what health care providers & researchers have to say about epigenetics

“The current study reveals the importance of gene regulation by epigenetic rather than genetic mechanisms enabling the cancer cells to readily adapt to new microenvironments of the various organs of the human body at sites away from the initial sites at which the cancer cells formed.”

“The knowledge that nutrition and lifestyle can regulate genes that fight the spread of cancer can dramatically empower patients. This new science, fused with computer technology, as pioneered by Epigenetic Data Sciences, offers a powerful new tool for people to use in optimizing the therapeutic benefits of diet and dietary supplementation.”

“Now that we have identified a new mechanism directly connecting an oncogenic signaling pathway with epigenetic regulation in ER-positive breast cancer, we can explore the possibility of targeted and personalized therapies with a more limited chance of resistance in this setting.”

“The knowledge that nutrition and lifestyle can regulate genes that fight the spread of cancer can dramatically empower patients. This new science, fused with computer technology, as pioneered by Epigenetic Data Sciences, offers a powerful new tool for people to use in optimizing the therapeutic benefits of diet and dietary supplementation.”

“The current study reveals the importance of gene regulation by epigenetic rather than genetic mechanisms enabling the cancer cells to readily adapt to new microenvironments of the various organs of the human body at sites away from the initial sites at which the cancer cells formed.”

“Now that we have identified a new mechanism directly connecting an oncogenic signaling pathway with epigenetic regulation in ER-positive breast cancer, we can explore the possibility of targeted and personalized therapies with a more limited chance of resistance in this setting.”

Close Menu